- Home
- LPTX vs BNC Comparison
LPTX vs BNC Comparison
Compare LPTX & BNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- BNC
- Stock Information
- Founded
- LPTX 2011
- BNC N/A
- Country
- LPTX United States
- BNC United States
- Employees
- LPTX N/A
- BNC N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- BNC Industrial Machinery/Components
- Sector
- LPTX Health Care
- BNC Industrials
- Exchange
- LPTX Nasdaq
- BNC Nasdaq
- Market Cap
- LPTX 14.7M
- BNC 13.7M
- IPO Year
- LPTX N/A
- BNC N/A
- Fundamental
- Price
- LPTX $0.31
- BNC $27.34
- Analyst Decision
- LPTX Hold
- BNC
- Analyst Count
- LPTX 1
- BNC 0
- Target Price
- LPTX N/A
- BNC N/A
- AVG Volume (30 Days)
- LPTX 661.1K
- BNC 1.0M
- Earning Date
- LPTX 08-19-2025
- BNC 08-22-2025
- Dividend Yield
- LPTX N/A
- BNC N/A
- EPS Growth
- LPTX N/A
- BNC N/A
- EPS
- LPTX N/A
- BNC N/A
- Revenue
- LPTX N/A
- BNC $3,478,254.00
- Revenue This Year
- LPTX N/A
- BNC N/A
- Revenue Next Year
- LPTX N/A
- BNC N/A
- P/E Ratio
- LPTX N/A
- BNC N/A
- Revenue Growth
- LPTX N/A
- BNC 10.08
- 52 Week Low
- LPTX $0.22
- BNC $5.60
- 52 Week High
- LPTX $4.79
- BNC $82.88
- Technical
- Relative Strength Index (RSI)
- LPTX 43.86
- BNC N/A
- Support Level
- LPTX $0.30
- BNC N/A
- Resistance Level
- LPTX $0.37
- BNC N/A
- Average True Range (ATR)
- LPTX 0.03
- BNC 0.00
- MACD
- LPTX -0.00
- BNC 0.00
- Stochastic Oscillator
- LPTX 28.53
- BNC 0.00
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.